10 Stocks Investors Are Gobbling Up

5. Tempus AI, Inc. (NASDAQ:TEM)

Shares of Tempus AI surged to a seven-month high on Thursday, jumping 13.59 percent to close at $88.78 apiece as investors cheered the Food and Drug Administration’s (FDA) green light for the updated version of Tempus Pixel, its AI-powered cardiac imaging platform.

During the session, the stock touched a high of $91.06, or just 39 cents shy of its 52-week high of $91.45.

In a statement, Tempus AI, Inc. (NASDAQ:TEM) said the FDA has given the 501(k) clearance for the updated version of the Tempus Pixel, allowing the generation of T1 and T2 inline maps and enhancing the device’s capabilities for cardiac MR image analysis.

Unlike conventional MR images that only show brightness differences, Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization.

It also enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights.

“This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful,” said Chris Scotto DiVetta, senior vice president for AI Applications at Tempus AI, Inc. (NASDAQ:TEM).

“With inline maps generated by Tempus Pixel, cardiologists and radiologists gain a comprehensive view of heart tissue, enabling deeper insights into cardiac health and helping them deliver more precise, personalized care to their patients.”